High Growth Tech Stocks Featuring Three Prominent US Companies

Over the last 7 days, the United States market has risen 5.7%, contributing to a remarkable 37% increase over the past year, with earnings forecasted to grow by 16% annually. In this dynamic environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these favorable market conditions.

Top 10 High Growth Tech Companies In The United States

Click here to see the full list of 243 stocks from our US High Growth Tech and AI Stocks screener.

Here we highlight a subset of our preferred stocks from the screener.

Rhythm Pharmaceuticals (NasdaqGM:RYTM)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company specializing in therapies for rare neuroendocrine diseases, with a market capitalization of approximately $4.14 billion.

Operations: Rhythm Pharmaceuticals generates revenue primarily through the development and commercialization of therapies for patients with rare diseases, totaling $112.53 million. The company’s operations are centered on addressing rare neuroendocrine conditions.

Rhythm Pharmaceuticals stands out in the high-growth tech sector, primarily due to its innovative approach in tackling rare genetic disorders of obesity. With a projected annual revenue growth rate of 46.1%, Rhythm is pacing well above the US market average of 8.9%. This robust expansion is supported by significant R&D investments, which are crucial for advancing their pipeline and maintaining competitive edge in biotech innovation. The company’s recent earnings report revealed a revenue increase to $88.3 million from $53.19 million year-over-year, underscoring strong market demand for its specialized treatments like IMCIVREE® (setmelanotide). Moreover, earnings are expected to surge by 66.7% annually, highlighting potential profitability within three years—a testament to their strategic focus on addressing unmet medical needs through scientific research and development.

• Delve into the full analysis health report here for a deeper understanding of Rhythm Pharmaceuticals.

• Gain insights into Rhythm Pharmaceuticals’ historical performance by reviewing our past performance report.

Krystal Biotech (NasdaqGS:KRYS)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Krystal Biotech, Inc. is a commercial-stage biotechnology company focused on discovering, developing, and commercializing genetic medicines for rare diseases in the United States, with a market capitalization of approximately $5.74 billion.

Operations: Krystal Biotech generates revenue primarily from its business of developing and commercializing pharmaceuticals, amounting to $241.52 million. The company focuses on genetic medicines targeting rare diseases in the U.S.

Krystal Biotech has demonstrated a robust trajectory in the biotech sector, with its revenue forecast to grow at 32.4% annually, significantly outpacing the US market average of 8.9%. This growth is underpinned by a sharp focus on R&D, where expenses are strategically aligned with long-term innovation goals—evident from recent presentations at high-profile healthcare conferences. Impressively, Krystal turned profitable this year, with earnings expected to surge by 41.2% annually over the next three years. The company’s recent financial performance includes a notable increase in net income to $43.68 million for the nine months ending September 2024, up from $2.24 million in the same period last year, reflecting strong operational execution and market demand for its pioneering treatments.

• Navigate through the intricacies of Krystal Biotech with our comprehensive health report here.

• Gain insights into Krystal Biotech’s past trends and performance with our Past report.

Neurocrine Biosciences (NasdaqGS:NBIX)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Neurocrine Biosciences, Inc. focuses on discovering, developing, and marketing pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders globally with a market cap of approximately $12.73 billion.

Operations: The company generates revenue primarily through the research, development, and commercialization of pharmaceuticals, with a reported revenue of $2.24 billion. Its business operations are centered on addressing neurological, neuroendocrine, and neuropsychiatric disorders both in the U.S. and internationally.

Neurocrine Biosciences has been making significant strides in the biopharmaceutical sector, particularly with its INGREZZA® capsules, showing promising results in recent studies. The company’s focus on neurological and endocrine-related diseases is reflected in its robust R&D spending, which accounted for 14.2% of its revenue last year. This investment is yielding tangible outcomes as demonstrated by the positive data from the KINECT®-HD study at recent medical conferences, enhancing Neurocrine’s profile in treating movement disorders like Huntington’s disease. Moreover, with a projected annual earnings growth of 29.9%, Neurocrine is not just innovating but also growing at a pace that suggests a promising horizon for both treatments and shareholders alike.

• Click to explore a detailed breakdown of our findings in Neurocrine Biosciences’ health report.

• Review our historical performance report to gain insights into Neurocrine Biosciences”s past performance.

Seize The Opportunity

• Delve into our full catalog of 243 US High Growth Tech and AI Stocks here.
• Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio’s performance.
• Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.

Looking For Alternative Opportunities?

• Explore high-performing small cap companies that haven’t yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com